New Phototherapy Device to Treat Patients With Crigler-Najjar Disease

Not Applicable

• Conditions: Crigler Najjar Syndrome; Children

• Registration Number: NCT02356978
• Lead Sponsor: Assistance Publique - Hôpitaux de Paris

Brief Summary

Evaluating the efficacity of a new device phototherapy by comparing it with conventional phototherapy. Jaundice occurs in many newborns, and is, in most cases benign, However, owing to the potential neurotoxicity of unconjugated bilirubin, newborns must be monitored to identify those who might develop severe hyperbilirubinemia an, in rare cases, acute bilirubin encephalopathy or kernicterus. Treatment of jaundice in newborn relies on phototherapy, exposing their skin to light of a specific wavelength . Fluorescent tubes or halogen lamps have been used as light sources for phototherapy for many years. Light-emitting diodes (LEDs) are more recent sources which are power efficient, have a longer life and are portable with low heat production. Several technologies and devices are developed using LEDs and specially a compact system.

Detailed Description

Crigler-Najjar (CN) syndrome is a congenital inborn error of hepatic bilirubin metabolism caused by the deficiency of bilirubin uridinediphosphate glucuronosyltransferase activity CN patients are at permanent risk of life-threatening bilirubin encephalopathy (kernicterus). Treatment of CN disease relies on daily prolonged phototherapy (10-12 h/day). To date, liver transplantation is the only curative treatment available. To date, no phototherapy device exists for teenagers and adults. CN patients use homemade systems or add several neonatal systems together to reach a better efficacy.

A new device has been designed by weaving optical fibers into a sheet connected to LEDs. This new technology, marketed by several manufacturers of phototherapy devices, is used in pediatric wards for treating jaundiced newborns. A prototype of 80× 100cm was thus developed, which combines numerous advantages : important surface of treatment, easy use and transportation, user-friendliness.

Before going to a therapeutic trial for assessing the benefits of this new device in ambulatory current practice, it is essential to make sure of both its feasibility and efficiency on the control of bilirubinemia, under medical supervision.

Hypothesis: the new phototherapy sheet is as effective as, and better tolerated than the usual devices used in CN patients.

Study Timeline

• Study Start: 2014-12
• Study First Submitted: 2015-02-02
• Study First Submitted QC: 2015-02-05
• Study First Posted: 2015-02-06
• Status Verified: 2016-12
• Last Update Submitted: 2017-09-11
• Last Update Posted: 2017-09-12
• Primary Completion: 2017-12
• Study Completion: 2017-12

Recruitment & Eligibility

• Status: UNKNOWN
• Sex: All
• Target Recruitment: 6

Inclusion Criteria

• genetic diagnosis of Crigler Najjar disease
• child whose height is between 60cm and 100cm
• patients with follow-up in reference center,

Exclusion Criteria

• opposition of parents
• no social security insurance

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: SINGLE_GROUP

Primary Outcome Measures

Name	Time	Method
Kinetic of blood Bilirubin level using the "DRAP" device (blood bilirubin concentration)	Before using "DRAP" device (H0), and after using (Hour12, Hour 36, Hour 48, Hour 60, Hour 72, Hour 84, Hour 96)	blood bilirubin concentration will be measured 2 times during phototherapy treatment (before and after phototherapy)

Trial Locations

Locations (1)

AP-HP, Antoine Béclère Hospital; 🇫🇷 Clamart, France